Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Braulio Mestre Fernández"'
Autor:
Elías A. Gracia Medina, Brenda Benítez Caballero, Karen López Miguel, Zaili Aleaga Gutiérrez, Braulio Mestre Fernández, Luis E. Alsina Tul, Luis E. Martín Rodríguez, Orlando Valdés Guerrero, Idania G. Sánchez Varela, María de la Caridad Campos Bernardo, Yoandri Calderón Montero, Mónica Ramos Ortiz, Julien Martínez Carrasco, Keytia Peña Torres, Yenia I. Díaz Prado, María Caridad Rubio, Inés M. Pérez Braojo
Publikováno v:
Cancer Treatment and Research Communications, Vol 34, Iss , Pp 100670- (2023)
PURPOSE: Dual HER2 blockade chemotherapy is the standard of care for localized HER2+ breast cancer (BC). However, despite the efficacy of neoadjuvant therapy, relapses occurring in around 10% of patients highlight the need to improve its clinical app
Externí odkaz:
https://doaj.org/article/eae1f9a3cbab4ede850c096eb5bfbbb8
Autor:
Tania Crombet Ramos, Braulio Mestre Fernández, Zaima Mazorra Herrera, Normando E. Iznaga Escobar
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasis of the cancer cells. Nimotuzumab is an engineered, intermediate affinity anti-EGFR antibody, that apart from other drugs in its class, is very safe an
Externí odkaz:
https://doaj.org/article/bceb0de3d3f9425f805305ce0060dcf0
Autor:
Braulio Mestre Fernández, Zaima Mazorra Herrera, Normando E Iznaga Escobar, Tania Crombet Ramos
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasis of the cancer cells. Nimotuzumab is an engineered, intermediate affinity anti-EGFR antibody, that apart from other drugs in its class, is very safe an